[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

August 17, 2017
Cancer Care Chronicles

Patients With Lung Cancer Need Love Too

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.2331
Original Investigation

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaUpdated Results From a Phase 1/2 Open-label Study

Abstract Full Text
free access
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.2411

This phase 1/2 open-label study reports a planned update of the safety and efficacy of durvalumab in patients with locally advanced/metastatic urothelial carcinoma who had progressed on, were ineligible for, or refused prior chemotherapy.

Brief Report

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.2391

This study addressed toxic effects and time to treatment failure in patients with melanoma treated with nivolumab plus ipilimumab.

JAMA Oncology Clinical Challenge

An Erysipeloid Cutaneous Eruption in a Woman With Advanced Breast Cancer

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.2325

A woman in her 60s with a history of metastatic breast cancer presented with a 3-month history of a progressive, asymptomatic cutaneous eruption of nontender discrete erysipeloid plaques on her chest and back. What is your diagnosis?

Comment & Response

Is “Do Everything!” Always Appropriate?

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.1647

The Bitter, Expensive Pill at the End of Life

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.1650

Is “Do Everything!” Always Appropriate?—Reply

Abstract Full Text
JAMA Oncol. Published online August 17, 2017. doi:10.1001/jamaoncol.2017.2349
August 10, 2017
Original Investigation

Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver DamageA Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2303

This phase 2 clinical trial evaluated the safety and efficacy of individualized adaptive stereotactic body radiotherapy for liver tumors in patients who have preexisting liver dysfunction.

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal CancerResults From the C SCANS Study

Abstract Full Text
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2319

This cohort study of patients with early-stage colorectal cancer examines whether prediagnostic systemic inflammation is associated with at-diagnosis sarcopenia and explores whether these factors interact to predict cancer survival.

JAMA Oncology Clinical Challenge

New Painful Nodules in a Patient With Multiple Myeloma

Abstract Full Text
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2112

A woman in her 60s presented with multiple painful cutaneous nodules and a history of IgGκ multiple myeloma. What is your diagnosis?

Research Letter

Out-of-Pocket Costs, Financial Distress, and Underinsurance in Cancer Care

Abstract Full Text
free access
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2148

This cross-sectional survey study examines financial distress and cost expectations among patients with cancer presenting for anticancer therapy.

Comment & Response

Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: Is Survivin the Ariadne's Thread?

Abstract Full Text
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2313

Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: Is Survivin the Ariadne's Thread?—Reply

Abstract Full Text
JAMA Oncol. Published online August 10, 2017. doi:10.1001/jamaoncol.2017.2316
August 3, 2017
Original Investigation

Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.1350

This cohort study evaluates baseline surveillance methods for cancer detection in patients with Li-Fraumeni syndrome.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance ImagingA Meta-analysis

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.1968

This meta-analysis assesses the clinical utility of whole-body magnetic resonance imaging in 13 cohorts of germline TP53 mutation carriers.

Brief Report

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch SyndromeImplications for Stratified Surveillance Strategies

Abstract Full Text
open access
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.0619

In this cohort study of patients with Lynch syndrome with colorectal, endometrial, and/or ovarian cancer, mutation genes and types are evaluated for their association with age at cancer onset.

Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.0769

This population-based study evaluates the risk of cancer in families who are positive for Amsterdam criteria for Lynch syndrome.

Invited Commentary

Cancer Screening in Li-Fraumeni Syndrome

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.2459
Research Letter

Surveillance of Dutch Patients With Li-Fraumeni SyndromeThe LiFe-Guard Study

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.1346

This cohort study of patients with Li-Fraumeni syndrome assesses the diagnostic yield and false-positive rate of an annual surveillance program including whole-body magnetic resonance imaging in patients identified as carriers of TP53 gene mutations.

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.1355

This prospective study of surveillance strategies uses a whole-body screening program, including whole-body magnetic resonance imaging, in carriers of germline mutations in TP53.

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome SpectrumPreliminary Data of the LIFSCREEN Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online August 3, 2017. doi:10.1001/jamaoncol.2017.1358

This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.

×